Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 525,910

Document Document Title
WO/2021/054534A3
The present invention provides an efinaconazole-containing solution-type topically-administered pharmaceutical composition comprising: a combination of diethylene glycol monoethyl ether and isopropyl myristate as a nonvolatile solvent; a...  
WO/2021/092115A1
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.  
WO/2021/092360A1
The present application is directed to reducing virus levels and treating virus infection in a subject. This treatment achieved by targeting cellular host factors in the subject, these being GRP78/BIP, SRSF1, HNRNP A2B 1, RPLP1 and RPLP2...  
WO/2021/088885A1
The present invention relates to the technical field of chemical medicine, in particular to a compound targeting type I PRMT, a preparation method therefor, and an application thereof. The compound A and a pharmaceutically acceptable sal...  
WO/2020/231776A8
Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a ga...  
WO/2021/092287A1
Compounds of Formula IA, IB, II, III, IV, and/or V are described herein along with their methods of use. A compound of the present invention may cross-link under physiological conditions and/or in vivo.  
WO/2021/092496A1
Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders. Furt...  
WO/2021/091586A1
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.  
WO/2021/092439A1
In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-iso...  
WO/2021/091904A1
Aspects of the disclosure include methods for treating a myeloproliferative neoplasm. Methods according to certain embodiments include co-administering to a subject a Janus kinase (JAK) inhibitor and a telomerase inhibitor comprising an ...  
WO/2021/092030A1
The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.  
WO/2021/088845A1
An imidazolidinone compound as represented by formula (I) or a stereoisomer, a geometric isomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, a synthetic metho...  
WO/2021/091908A1
The present disclosure provides peripherally acting cannabidiol (CBD)-containing compositions and methods of using thereof for treating or enhancing female sexual function. In some embodiments, the compositions are provided in the form o...  
WO/2021/091881A1
A method of providing a high concentration disulfide-linked caspase inhibitor-cell penetrating peptide conjugate is described. The method includes incubating a caspase inhibitor having one or more thiol groups with a reducing agent selec...  
WO/2021/092145A1
The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR- associated ocular diseases.  
WO/2021/092354A1
Provided herein are methods and compositions related to the administration of uricase compositions and compositions comprising synthetic nanocarriers comprising an immunosuppressant for the treatment of subjects, including subjects with ...  
WO/2021/092598A1
Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable salt thereof to a subject in need thereof and diagnostic methods useful in conne...  
WO/2021/092090A1
Disclosed herein are methods for palmar or plantar administration of anticholinergic compounds to a subject in need thereof. Also disclosed herein are methods of treating palmar or plantar hyperhidrosis in a subject in need thereof by ad...  
WO/2021/091902A1
In general, the invention relates to pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI), muscarinic receptor antagonist, and carbonic anhydrase inhibitor and methods of treating Sleep Apnea comprising the ad...  
WO/2021/089828A1
Provided is a compound for use in preventing, treating or delaying progression of a disease involving aberrant fibroblast proliferation. The compound is a compound effective in reducing the level of 5 tyrosine phosphatase activity effect...  
WO/2021/092110A1
The present invention is related to a nuclease-activated culture substrate, a method of rapidly detecting an antibiotic-resistant microorganism using the nuclease-activated culture substrate, and kits including the nuclease-activated cul...  
WO/2021/092522A1
One aspect of the present disclosure is directed to a method of delivering tofacitinib to or through a skin. Another aspect of the present disclosure is directed to a method of locally inhibiting activity of at least one of JAK-1, JAK-2,...  
WO/2021/091510A1
The present invention relates to a pharmaceutical capsule composition comprising eltrombopag olamine and at least one binder for use in the treatment of thrombocytopenia.  
WO/2021/088787A1
Disclosed is a quinazoline compound used as an AXL inhibitor. The structure of the quinazoline compound is as shown in general formula (I), and the definition of each substituent is as described in the description. Further provided is a ...  
WO/2021/091958A1
The present disclosure provides RIG-I antagonists. In certain embodiments, the antagonists of the disclosure can be used to treat or prevent a disease or disorder in a subject.  
WO/2021/091358A1
The present invention relates to a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically ac...  
WO/2021/089513A1
The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and lenalidomide.  
WO/2021/088753A1
Disclosed are benzothiazole compounds, and a preparation method therefor and the anti-tuberculosis use thereof. The benzothiazole compounds are as shown below, and are highly effective, have a low toxicity and are stable anti-tuberculosi...  
WO/2021/091956A1
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.  
WO/2021/092417A1
Methods of treating a Pseudomonas bacterial infection and/or eliciting an immune response in a subject are provided and include administering to the subject a vaccine including a modified Pseudomonas bacterium missing or deficient in alp...  
WO/2021/092349A1
Compositions comprising pharmaceutically acceptable salts of SCY-078, a glucan synthase inhibitor, and methods comprising the same for treating and/or preventing, among other things, Invasive Candidiasis and Invasive Aspergillosis are di...  
WO/2021/089824A1
The present invention relates to agonists of the 5-HT2Aserotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In another aspect, the invention relates to 5-HT2A agonists for use...  
WO/2021/089794A1
The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder canc...  
WO/2020/140005A8
The present invention relates to compounds of Formula (II) and more preferably to 1H-pyrrolo[2,3-b]pyridine derivatives of formula (III) and related compounds. The variables are defined in the claims. The compounds are BCL-2 inhibitors f...  
WO/2021/092054A1
A composition comprising a plurality of discrete particles comprising one or more cannabinoids disposed at least partially within a polymeric carrier having a maximum overall dimension of less than 1 micron. A composition comprising a pl...  
WO/2021/089873A1
The present invention relates to the synthesis of compounds of formula III from compounds of formula I via compounds of formula II. The present invention also relates to particular compounds of formula III, or pharmaceutically acceptable...  
WO/2021/088983A1
Disclosed is a 7,8-dihydroxyflavone composite nano-biomaterial with high bioavailability, a preparation method thereof, and an application thereof Specifically, the material uses zein and lactoferrin as packaging material and uses 7,8-di...  
WO/2021/090283A1
The present invention provides shortening TB Therapy and reducing relapse by co-administering Chloroquine with anti-TB drugs to drug-sensitive TB patients, multiple drug resistant (MDR) TB patients and TB patients co-infected with HIV-1....  
WO/2021/092062A1
Compositions may include a therapeutic that is released from the composition to treat any number of ailments or conditions (e.g., pain, infection, cancer, osteoporosis) or to help accelerate local tissue regeneration (e.g., growth hormon...  
WO/2021/089736A1
The present invention relates to the treatment of muscular diseases.  
WO/2021/088920A1
A nitrogen-containing ring derivative regulator, a preparation method therefor and use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceut...  
WO/2021/092153A1
The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylases 6 and 8 (HDAC6/8) activity.  
WO/2021/089053A1
Disclosed is a nano complex for the targeted repairing of a neurovascular lesion. The nano complex comprises a lipid, an apolipoprotein and a targeted peptide, and the targeted peptide is formed by covalently linking, by means of a bridg...  
WO/2021/091316A1
The present invention relates to a composition, comprising TMEM176B as an active ingredient, for prevention or treatment of degenerative brain disease. A composition according to an embodiment promotes the phagocytic action of astrocytes...  
WO/2021/090301A1
The present invention provides a low dose topical composition of Apremilast with pharmaceutically acceptable excipients. The present invention also relates to a topical clear gel composition of apremilast for delivering a desired therape...  
WO/2021/089790A1
The present invention relates to compounds having a lipid affinity of less than 15% by weight of the compound (such as a logP of -0.75 or less) for use in targeting mitochondria to reduce, inhibit or prevent the formation of mitochondria...  
WO/2021/088957A1
Disclosed are a novel aromatic heterocyclic compound as an ATX (Autotaxin) inhibitor, a pharmaceutical composition containing the compound, and a use of the compound and the composition in treatment of a disease having a pathological cha...  
WO/2021/092246A1
Described herein are TYK2 pseudokinase ligands and methods of utilizing TYK2 pseudokinase ligands in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.  
WO/2021/092240A1
The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 an...  
WO/2021/071788A3
Among other things, the present disclosure provides C9orf72 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides methods for treating C9orf72-associated conditions, disorders or diseas...  

Matches 1 - 50 out of 525,910